OncoMatch/Clinical Trials/NCT05512208
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Is NCT05512208 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Avutometinib (VS-6766) + defactinib for endometrioid cancer.
Treatment: Avutometinib (VS-6766) + defactinib — The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Cervical Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
mutated RAS
Required: NRAS mutation
mutated RAS
Required: HRAS mutation
mutated RAS
Required: BRAF type I mutation
BRAF (type I, II, and/or III)
Required: BRAF type II mutation
BRAF (type I, II, and/or III)
Required: BRAF type III mutation
BRAF (type I, II, and/or III)
Required: NF1 loss of function
NF-1 loss of function
Required: KRAS activation
RAS activation
Required: NRAS activation
RAS activation
Required: HRAS activation
RAS activation
Disease stage
Required: Stage FIGO STAGE II-IV (FIGO)
Metastatic disease required
metastatic disease (FIGO stage II-IV)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — metastatic
Cannot have received: mek inhibitor
Cannot have received: raf inhibitor
Lab requirements
Blood counts
hemoglobin ≥9.0 g/dL; platelets ≥100,000/mm3; ANC ≥1500/mm3
Kidney function
creatinine clearance rate of ≥50 mL/min (Cockcroft-Gault) or serum creatinine ≤ 1.5 x ULN
Liver function
total bilirubin ≤1.5 × ULN (subjects with Gilbert syndrome may enroll if total bilirubin is <3.0 mg/dL); ALT and AST ≤2.5 × ULN (or <5x ULN in subjects with liver metastases)
Cardiac function
left ventricular ejection fraction ≥ 55% by ECHO or MUGA scan; baseline QTc interval < 460 ms (average of triplicate readings) (CTCAE Grade1) using Fredericia's QT correction formula
Must have adequate organ function defined by the following laboratory parameters: ... see protocol for full details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- AdventHealth · Orlando, Florida
- Louisiana State University Medical Center New Orleans · New Orleans, Louisiana
- University of New Mexico Comprehensive Cancer Center · Albuquerque, New Mexico
- Stephenson Cancer Center · Oklahoma City, Oklahoma
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify